GlobalData on MSN6h
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useThe US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a prescription drug user fee act (PDUFA) target action date of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback